Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Nutrien Ltd. (NYSE:NTR - Free Report) by 78.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,495,282 shares of the company's stock after buying an additional 1,100,000 shares during the quarter. Nutrien comprises 1.1% of Clal Insurance Enterprises Holdings Ltd's portfolio, making the stock its 27th largest holding. Clal Insurance Enterprises Holdings Ltd owned approximately 0.51% of Nutrien worth $121,271,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of NTR. Lester Murray Antman dba SimplyRich raised its stake in Nutrien by 2.3% in the second quarter. Lester Murray Antman dba SimplyRich now owns 9,069 shares of the company's stock valued at $461,000 after purchasing an additional 202 shares in the last quarter. FFT Wealth Management LLC lifted its holdings in shares of Nutrien by 0.8% during the 2nd quarter. FFT Wealth Management LLC now owns 29,220 shares of the company's stock worth $1,488,000 after acquiring an additional 220 shares during the last quarter. Covestor Ltd grew its position in Nutrien by 33.3% in the first quarter. Covestor Ltd now owns 932 shares of the company's stock worth $50,000 after acquiring an additional 233 shares in the last quarter. MONECO Advisors LLC increased its stake in Nutrien by 2.4% in the second quarter. MONECO Advisors LLC now owns 9,791 shares of the company's stock valued at $498,000 after acquiring an additional 233 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its position in Nutrien by 6.5% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,309 shares of the company's stock valued at $207,000 after purchasing an additional 263 shares in the last quarter. 63.10% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. UBS Group lowered Nutrien from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $66.00 to $51.00 in a research report on Thursday, October 10th. Hsbc Global Res downgraded shares of Nutrien from a "hold" rating to a "moderate sell" rating in a research note on Friday, August 2nd. Wells Fargo & Company lowered shares of Nutrien from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $62.00 to $50.00 in a report on Tuesday, September 24th. The Goldman Sachs Group lowered shares of Nutrien from a "buy" rating to a "neutral" rating and cut their price target for the company from $69.00 to $53.00 in a research report on Tuesday, September 10th. Finally, Scotiabank reduced their price target on Nutrien from $66.00 to $59.00 and set a "sector outperform" rating on the stock in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $60.33.
Get Our Latest Stock Report on NTR
Nutrien Stock Up 0.1 %
Shares of NYSE:NTR traded up $0.06 during trading on Friday, hitting $46.93. The stock had a trading volume of 1,403,974 shares, compared to its average volume of 2,320,350. The company has a market capitalization of $23.18 billion, a PE ratio of 31.50, a PEG ratio of 1.65 and a beta of 0.82. The company has a quick ratio of 0.82, a current ratio of 1.27 and a debt-to-equity ratio of 0.38. The firm's fifty day moving average is $48.01 and its 200 day moving average is $50.15. Nutrien Ltd. has a 12 month low of $44.65 and a 12 month high of $60.87.
Nutrien (NYSE:NTR - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.43 by ($0.04). Nutrien had a return on equity of 6.99% and a net margin of 2.79%. The firm had revenue of $5.35 billion during the quarter, compared to the consensus estimate of $5.26 billion. During the same quarter last year, the company posted $0.35 EPS. Nutrien's revenue for the quarter was down 5.0% compared to the same quarter last year. Analysts anticipate that Nutrien Ltd. will post 3.56 EPS for the current fiscal year.
Nutrien Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, January 17th. Shareholders of record on Tuesday, December 31st will be issued a $0.939 dividend. This represents a $3.76 annualized dividend and a yield of 8.00%. This is an increase from Nutrien's previous quarterly dividend of $0.54. The ex-dividend date is Tuesday, December 31st. Nutrien's payout ratio is 144.97%.
About Nutrien
(
Free Report)
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment distributes crop nutrients, crop protection products, seeds, and merchandise products. The Potash segment provides granular and standard potash products.
Featured Articles
Before you consider Nutrien, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutrien wasn't on the list.
While Nutrien currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.